Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
ConditionPancreas Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Louisville
About this trial
Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Eligibility criteria
Qualifiers
greater than or equal to 18 years of age
diagnosed with stage III pancreatic cancer
tumor is measurable
GFR > mL/min/1.73m2
Disqualifiers
participating in another clinical trial for the treatment of cancer at the time of screening
pregnant or currently breast feeding
have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure
have non-removable implants with metal parts within 1 cm of the target lesion
Trial design
Treatments tested in this trial
- Irreversible Electroporation (IRE)
- Gemcitabine
- FOLFIRINOX
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov